Immunomedics announces third quarter fiscal 2012 results and clinical program developments (Immunomedics) - May 8, 2012 - P1/2, N=70; IM-T-hA20/90Y-hLL2-01; Initial clinical experience of 90Y-labeled epratuzumab combined with veltuzumab in pts with aggressive lymphoma will be reported in an oral presentation at the 59th Annual Meeting of the Society of Nuclear Medicine (SNM) on Wed, Jun 13, 2012
Anticipated P1/2 data presentation • Hematological Malignancies • Non-Hodgkin's Lymphoma
|
|
The Company's key clinical developments and future planned activities:
Epratuzumab tetraxetan
Initial clinical experience of 90Y-labeled epratuzumab combined with veltuzumab in patients with aggressive lymphoma will be reported in an oral presentation at the 59th Annual Meeting of the Society of Nuclear Medicine (SNM) on Wednesday, June 13, 2012.
Clivatuzumab tetraxetan
The new Phase Ib trial of 90Y-labeled clivatuzumab in patients with pancreatic cancer who have failed at least two prior therapies has been initiated.
The planned Phase III trial has been postponed until the new Phase Ib trial has been completed. The Company believes this is not only responsive to our advisors' recommendations, but may ultimately provide a shortened clinical development program for this promising agent in pancreatic cancer therapy, especially since our first Phase I study of the radiolabeled antibody given by itself to patients relapsing to prior therapies showed evidence of therapeutic activity.
Full survival data from the Phase Ib/II frontline study of yttrium-90-labeled clivatuzumab combined with gemcitabine in advanced pancreatic cancer will be presented at the following medical conferences:
-- 2012 Annual Meeting of the American Society of Clinical Oncology -- Monday, June 4, 2012, poster presentation
-- 59th Annual Meeting of SNM -- Wednesday, June 13, 2012, oral presentation
-- 14th World Congress on Gastrointestinal Cancer organized by the European Society of Medical Oncology -- Wednesday, June 27, 2012, oral presentation.
Veltuzumab
Takeda-Nycomed is expected to enroll patients with rheumatoid arthritis into the Phase II VELVET study in the second half of 2012.
|